Danaher to Launch AI-Powered Autonomous Research Lab in 2027

The autonomous lab forms part of a broader Danaher programme to develop smart instruments that can be connected through AI-ready data, programmatic controls and agentic systems.

US-based life sciences company Danaher has announced plans to launch its first AI-powered autonomous research lab at scale in early 2027, bringing AI, robotics, and life sciences technologies together to accelerate the development of custom antibodies and other molecular tools.

Danaher’s AI-powered autonomous research lab is expected to make the discovery of affinity reagents up to eight times faster while enabling up to a tenfold increase in annual reagent generation.

The facility will use an automated design-make-test-learn cycle, allowing each experimental result to improve the next molecular design.

“The autonomous lab reflects the kind of progress Danaher is uniquely positioned to deliver,” said Julie Sawyer Montgomery, President and Chief Executive Officer of Danaher. “By applying our science, technology and culture of continuous improvement, we can help turn promising ideas into validated systems faster. It is an important step toward a future where AI, automation and intelligent systems dramatically accelerate the journey from discovery to impact.”

The lab will be based at Abcam, a Danaher company, and will combine technologies from several businesses across Danaher’s life sciences ecosystem.

These include Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies and Molecular Devices, alongside robotic automation developed through collaboration with Automata.

Abcam brings particular expertise in antibody and protein research to the initiative. Danaher completed its acquisition of Abcam in December 2023 after announcing a deal valued at approximately $5.7 Bn.

Abcam provides antibodies, reagents, biomarkers and assays used in drug discovery, life sciences research and diagnostics, and joined Danaher as part of its Life Sciences segment.

Within the new lab, AI will help identify and design molecules capable of binding to specific biological targets. The selected designs will then be produced and experimentally tested, with the resulting data returned to the AI system.

This continuous feedback loop is intended to improve subsequent designs while reducing the time required to move from an initial scientific idea to a validated reagent.

Danaher said the system could increase reagent generation from tens to hundreds annually as the lab scales. The company also expects the approach to complement traditional antibody discovery methods over time, while maintaining verification and testing at each stage.

JC Gutierrez-Ramos, Senior Vice President and Chief Science Officer of Danaher, said, “This lab represents a new model for scientific discovery, where AI, automation and human expertise work together in a continuous learning cycle.”

He added, “That frees them to focus on the complex scientific challenges where human insight matters most.”

The autonomous lab forms part of a broader Danaher programme to develop smart instruments that can be connected through AI-ready data, programmatic controls and agentic systems.

The company aims to use these technologies to create integrated research workflows capable of executing increasingly automated scientific processes.

Stay tuned for more such updates on Digital Health News